PureTech Health PLC

NASDAQ PRTC

Data sourced from

and

Download Data

PureTech Health PLC Cash Per Share 1 year YoY Change (%) for the year ending December 31, 2023: 32.52%

PureTech Health PLC Cash Per Share 1 year YoY Change (%) is 32.52% for the year ending December 31, 2023, a 148.10% change year over year. The cash per share represents the amount of cash available to each outstanding share of common stock. It is calculated by dividing the total cash by the weighted average number of shares outstanding. This metric provides insight into the cash position of the company on a per-share basis and can be used to evaluate the company's liquidity and ability to distribute cash to shareholders. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

PureTech Health PLC Cash Per Share for the year ending December 31, 2022 was 5.26, a -67.61% change year over year.
PureTech Health PLC Cash Per Share for the year ending December 31, 2021 was 16.25, a 17.83% change year over year.
PureTech Health PLC Cash Per Share for the year ending December 31, 2020 was 13.79, a 204.02% change year over year.
PureTech Health PLC Cash Per Share for the year ending December 31, 2019 was 4.54, a 6.13% change year over year.

NASDAQ: PRTC

PureTech Health PLC

CEO	Ms. Daphne Zohar
IPO Date	Nov. 16, 2020
Location	United States
Headquarters	6 Tide Street, Boston, MA, United States, 02210
Employees	90
Sector	Healthcare
Industry	Biotechnology

Description

PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Key trends